Kyverna Therapeutics KYTX
NASDAQ KYTX
$8.25 -0.10 (-1.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025)

Kyverna Therapeutics' (KYTX) quarterly Asset Writedowns and Impairment came in at $648000.0 in Q1 2025.

Analysis

Kyverna Therapeutics (KYTX) Asset Writedowns and Impairment (2025) Analysis & Trends

Kyverna Therapeutics (KYTX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $648000.0 in Q1 2025.

  • Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $648000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $648000.0 (changed N/A YoY) and the FY2025 annual result came in at $648000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment steadied at $648000.0 in Q1 2025.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $648000.0 in Q1 2025 to a low of $648000.0 in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Kyverna Therapeutics 505.44 Mn 505.44 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 648,000.00